Search

Displaying results 4281 - 4290 of 10000 in total
  1. Drug

    Potassium triiodide

    go.drugbank.com/drugs/DB14492
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Sofalcone

    go.drugbank.com/drugs/DB05197
    Experimental

    Sofalcone is a mucosal protective agent that has been reported to inhibit growth of Helicobacter pylori. on adherence, production of vacuolating toxin (VT), and induction of interleukin-8 (IL-8) secretion

  3. Drug

    KC706

    go.drugbank.com/drugs/DB05157
    Investigational

    KC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase.

  4. Drug

    SR-123781A

    go.drugbank.com/drugs/DB05361
    Investigational

    SR-123781A is a synthetic hexadecasaccharide Factor IIa and Xa antagonist. It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).

  5. Drug

    Nalidixic acid

    go.drugbank.com/drugs/DB00779
    ApprovedWithdrawn

    Nalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.

    Synonyms: 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeureCategories: Topoisomerase II Inhibitors
  6. Drug

    Peptide YY (3-36)

    go.drugbank.com/drugs/DB05004
    Investigational

    Peptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity. It reduces appetite and increases satiety in obese patients.

  7. Drug

    LY2275796

    go.drugbank.com/drugs/DB05165
    Investigational

    LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that drive tumor progression, angiogenesis and metastases. … LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development.

  8. Drug

    IMC-1C11

    go.drugbank.com/drugs/DB06101
    Experimental

    It is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction and inhibits VEGFR-induced endothelial cell proliferation. … IMC-1C11 is an anti-angiogenesis agent.

  9. Drug

    Dolasetron

    go.drugbank.com/drugs/DB00757
    ApprovedInvestigational

    Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. … Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative

  10. Drug

    Nisin Z

    go.drugbank.com/drugs/DB19122
    Investigational

    Nisin Z is under investigation in clinical trial NCT06097468 (Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)).

    Synonyms: Nisin a, 27-l-asparagine-, Nisin, 27-l-asparagine-Categories: Compounds used in a research, industrial, or household setting